In this study, we present a preclinical evaluation of a rational combination of two novel compounds for the treatment of glioblastoma, that is, the Smac mimetic BV6, which antagonizes IAP proteins, and Drozitumab, a monoclonal antibody that specifically targets TRAIL-R2. This evidence concerns the gene TNFRSF10B and glioblastoma.